Otic Pharma LOGO

OticPharma’s mission is to develop ear, nose, and throat products that restore health and address unmet need in children and adults

An updated website is coming soon!
 

Mar 10, 2016 | OticPharma to Present at the 28th Annual ROTH Conference

IRVINE, Calif. and REHOVOT, Israel, March 10, 2016 /PRNewswire/ -- OticPharma, Ltd., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced that Gregory J. Flesher, chief executive officer, will provide an overview of the company at the upcoming 28th Annual ROTH Conference to be held at the Ritz-Carlton in Laguna Niguel, California.
------

Nov 30, 2015 | OticPharma Appoints Keith A. Katkin as Chairman of the Board of Directors

IRVINE, Calif. and REHOVOT, Israel, Nov. 30, 2015 /PRNewswire/ -- OticPharma, Ltd., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced the appointment of Keith A. Katkin as chairman of the company's board of directors.
------

Nov 11, 2015 | OticPharma Appoints Dr. Catherine C. Turkel as Chief Development Officer

IRVINE, Calif. and REHOVOT, Israel, Nov. 11, 2015 /PRNewswire/ -- OticPharma, Inc., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced that it has appointed Catherine C. Turkel, Pharm.D., Ph.D. to the position of senior vice president clinical research and development and chief development officer.
------

Nov 2, 2015 | OticPharma Acquires Novel Otitis Media Program from Otodyne, Inc.

IRVINE, Calif. and REHOVOT, Israel, Nov. 2, 2015 /PRNewswire/ -- OticPharma, Inc., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced that it has entered into a license agreement with Morristown, New Jersey based drug developer Otodyne, Inc., providing OticPharma with exclusive worldwide rights to develop and commercialize the company's investigational drug products for the treatment of otitis media and other conditions.
------

Sep 22, 2015 | OticPharma Announces Key Additions to the Senior Management Team

IRVINE, Calif. and REHOVOT, Israel, Sept. 22, 2015 /PRNewswire/ -- OticPharma, Ltd., a privately held company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced two new additions to the company's leadership team. Christine G. Ocampo joins OticPharma as senior vice president and chief financial officer. Michael Cruse also joins OticPharma as vice president of corporate operations.
------

Sep 3, 2015 | Israel-based OticPharma Establishes U.S. Footprint in California

IRVINE, Calif. and REHOVOT, Israel, September 3, 2015 / PRNewswire / -- OticPharma, Ltd, a privately held company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced it has selected the Irvine Company's Newport Gateway office complex to be the location of its new U.S. headquarters. OticPharma plans to complete the move by end of September and will have office locations in both U.S. and Israel.
------

 

U.S. Headquarters: 19900 MacArthur Blvd., Suite 550 Irvine, California 92612, USA | +1 949-238-8090 | info@oticpharma.com
Israel Office: 7 Oppenheimer St., Science Park Rehovot 7670107, Israel | +972-73-2903831
©2016 OticPharma, Inc. All rights reserved.